Plain-English translation of NCT02784210 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether a 3-day course of corticosteroids (either or ) can help reduce inflammation at the edges of multiple sclerosis brain lesions. Researchers believe that controlling this specific type of inflammation may help your brain heal better and prevent ongoing nerve damage. The study will use advanced brain MRI scans to see whether the medication changes how these lesions look and develop over 25 weeks.
Multiple sclerosis causes brain lesions where inflammation damages nerve tissue. Some of this inflammation persists even after the initial flare-up and seems to prevent healing and cause ongoing nerve damage. This medication is being studied to see if it can stop that lingering inflammation before it causes permanent harm.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to either receive a 3-day course of steroid medication or no treatment. Over approximately 25 weeks, you'll have brain MRI scans at different timepoints (some on standard scanners and some on higher-resolution scanners) to let researchers see how your lesions change. You'll also have clinical checkups and blood tests at baseline, week 13, and week 25. The study is conducted at a single research center.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States